Schrödinger discontinues leukemia drug after patient deaths

Schrödinger (SDGR) has discontinued the clinical development of its SGR-2921 drug candidate, a CDC7 inhibitor for AML/MDS, following two treatment-related patient deaths in its Phase 1 trial, citing patient safety. This termination, despite early monotherapy activity, represents a significant setback for the specific program. However, the company, which primarily develops computational drug discovery platforms, maintains a strong financial position with substantial cash reserves and robust revenue growth. Analysts largely retain a bullish outlook on SDGR, even as its stock experienced an after-hours decline despite recently beating Q2 2025 earnings expectations.

Analysis

Schrödinger, Inc. (SDGR) faces a significant clinical setback with the discontinuation of its SGR-2921 program for acute myeloid leukemia following two treatment-related patient deaths in the Phase 1 trial. This decision, driven by patient safety concerns, removes a pipeline asset despite early evidence of monotherapy activity and an assessment that combination therapy development would be difficult. This negative clinical development is counterbalanced by a robust financial profile. The company maintains a strong balance sheet with more cash than debt, a healthy current ratio of 3.3, and has demonstrated impressive revenue growth of 18.59% over the last twelve months. Furthermore, Schrödinger recently surpassed Q2 2025 analyst expectations, reporting a smaller-than-anticipated loss of $0.65 per share and revenue of $54.8 million, a 5.34% beat. Despite these strong fundamentals, the stock saw a slight after-hours decline, indicating that the market is weighing the clinical failure heavily. Analyst sentiment remains largely positive, with price targets ranging from $26 to $35 and a new 'Overweight' rating from Barclays, which anticipates potential positive catalysts in the fourth quarter of 2025.

Key Decisions for Investors

• Investors should evaluate Schrödinger based on the strength of its core computational platform and financial health, rather than focusing solely on the failure of the single clinical asset, SGR-2921.
• Monitor for the two potential catalysts anticipated in Q4 2025, as highlighted by Barclays, which could serve as the next major inflection point for the stock following this clinical setback.
• The divergence between the negative clinical news and the company's strong underlying financial performance, including recent revenue and earnings beats, may present a valuation dislocation and increased near-term volatility.